When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, our colleague Matthew Herper joins us to pick apart Gilead Sciences’ recent failure in the pervasive liver disease NASH and what it means for the many similar efforts in the pipeline. Then, STAT’s Megan Thielking stops by to talk about what could be the first novel treatment for depression in more than three decades, a ketamine-related drug from Johnson & Johnson. Later we hear from Dr. Eric Topol, a cardiologist and geneticist at the Scripps Research Institute in San Diego, about the chasm between hype and reality when it comes to AI in medicine. And then we bring you a lightning round, featuring the latest CRISPR patent drama, 2019’s crop of biotech IPOs, and a new term of art to in the biotech lexicon.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy